High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
暂无分享,去创建一个
B. Druker | M. Heinrich | D. Niederwieser | Matthias Mueller | H. Al-Ali | R. Krahl | T. Lange | Christel Müller | M. Deininger